Aplus: All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Study Details
Study Description
Brief Summary
This is a prospective, open-label, randomized controlled clinical intervention study to evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients with recurrent metastatic adenoid cystic carcinoma of the head and neck.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental group ATRA 20 mg, three times a day (tid), for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles; combined with the treatment regimen chosen by the investigator since Day 6 of cycle 1. |
Drug: All-trans Retinoic Acid
ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
Other Names:
|
| Active Comparator: Control group The investigator chooses the treatment regimen based on the following regimens (including but not limited to: 1. VEGFR inhibitor; 2. chemotherapy). |
Drug: VEGFR inhibitor
VEGFR inhibitor
Drug: Chemotherapy
chemotherapy
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate (CR+PR) [6 months]
Objective Response Rate as defined by RECIST 1.1 after induction therapy followed by definitive chemoradiation. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.
Secondary Outcome Measures
- Number of Participants With at Least One Grade 3-4 Toxicity [6 months]
Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.
- Progression-Free Survival [6 months]
Time to death or progression defined by imaging of target lesions via CT or MRI scan every 3 months.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years, male or female; 2. ECOG PS (performance status) score: 0-1; 3. Pathologically or histologically confirmed advanced, recurrent/metastatic ACC, with measurable disease (≥10 mm by spiral CT scan, meeting RECIST 1.1 criteria); 4. Patients with therapeutic indications; 5. Main organ functions normal, i.e., meeting the criteria below:
-
Criteria for routine blood test: (no blood transfusion within 14 days)
-
HB ≥ 90 g/L;
-
WBC ≥ 3.5 × 109/L and < 10 × 109/L;
-
ANC ≥ 1.5 × 109/L;
-
PLT ≥ 80 × 109/L
-
Criteria for biochemical tests:
-
BIL < 1.25 × upper limit of normal (ULN)
-
ALT and AST < 2.5 × ULN; in the presence of metastases to liver, ALT and AST < 5 × ULN;
-
Serum Cr ≤ 1 × ULN, endogenous creatinine clearance > 50 mL/min (Cockcroft-Gault equation); 5. Subjects who volunteer to participate in this study, sign the informed consent, have good compliance and cooperate in follow-up; 6. Patients who, in the doctor's opinion, can benefit from the treatment.
Exclusion Criteria:
-
Previous or existing concomitant malignancies except cured skin basal cell carcinoma or cervical carcinoma in situ;
-
Coagulation abnormal (INR>1.5, APTT>1.5×ULN), history of gastrointestinal hemorrhage in the past 6 months or bleeding tendency [e.g., presence of active ulcer focus in the stomach, stool occult blood (++), melena and/or hematemesis, hemoptysis in the past 3 months];
-
Confirmed hypersensitivity to ATRA;
-
Grade I and above coronary artery diseases, arrhythmias [including QTc prolongation (males: > 450 ms, females: > 470 ms)] and cardiac dysfunction;
-
Presence of multiple factors affecting oral administration (e.g. dysphagia, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.);
-
Pregnant or lactating women;
-
History of psychotropic abuse with abstinence failure, or existing mental disorder;
-
Participation in other drug clinical trials within 4 weeks;
-
Other concomitant diseases which seriously jeopardize the patient's safety or prevent the patient from completing the study, as judged by the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shanghai Ninth People's Hospital | Shanghai | Shanghai | China | 200011 |
Sponsors and Collaborators
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020HNRT02